Search Results - "Banks, Kimberly C"

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies by Odegaard, Justin I, Vincent, John J, Mortimer, Stefanie, Vowles, James V, Ulrich, Bryan C, Banks, Kimberly C, Fairclough, Stephen R, Zill, Oliver A, Sikora, Marcin, Mokhtari, Reza, Abdueva, Diana, Nagy, Rebecca J, Lee, Christine E, Kiedrowski, Lesli A, Paweletz, Cloud P, Eltoukhy, Helmy, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli

“…To analytically and clinically validate a circulating cell-free tumor DNA sequencing test for comprehensive tumor genotyping and demonstrate its clinical…”
Get full text

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients by Zill, Oliver A, Banks, Kimberly C, Fairclough, Stephen R, Mortimer, Stefanie A, Vowles, James V, Mokhtari, Reza, Gandara, David R, Mack, Philip C, Odegaard, Justin I, Nagy, Rebecca J, Baca, Arthur M, Eltoukhy, Helmy, Chudova, Darya I, Lanman, Richard B, Talasaz, AmirAli

“…Cell-free DNA (cfDNA) sequencing provides a noninvasive method for obtaining actionable genomic information to guide personalized cancer treatment, but the…”
Get full text

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases by Mack, Philip C., Banks, Kimberly C., Espenschied, Carin R., Burich, Rebekah A., Zill, Oliver A., Lee, Christine E., Riess, Jonathan W., Mortimer, Stefanie A., Talasaz, AmirAli, Lanman, Richard B., Gandara, David R.

“…Background Circulating cell‐free tumor DNA (ctDNA)‐based mutation profiling, if sufficiently sensitive and comprehensive, can efficiently identify genomic…”
Get full text

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers by Blakely, Collin M, Watkins, Thomas B K, Wu, Wei, Gini, Beatrice, Chabon, Jacob J, McCoach, Caroline E, McGranahan, Nicholas, Wilson, Gareth A, Birkbak, Nicolai J, Olivas, Victor R, Rotow, Julia, Maynard, Ashley, Wang, Victoria, Gubens, Matthew A, Banks, Kimberly C, Lanman, Richard B, Caulin, Aleah F, St John, John, Cordero, Anibal R, Giannikopoulos, Petros, Simmons, Andrew D, Mack, Philip C, Gandara, David R, Husain, Hatim, Doebele, Robert C, Riess, Jonathan W, Diehn, Maximilian, Swanton, Charles, Bivona, Trever G

“…Analysis of a large cohort of EGFR -mutant lung cancer cell-free DNA samples along with longitudinal samples from a patient with EGFR -mutant lung cancer…”
Get full text

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel by Willis, Jason, Lefterova, Martina I, Artyomenko, Alexander, Kasi, Pashtoon Murtaza, Nakamura, Yoshiaki, Mody, Kabir, Catenacci, Daniel V T, Fakih, Marwan, Barbacioru, Catalin, Zhao, Jing, Sikora, Marcin, Fairclough, Stephen R, Lee, Hyuk, Kim, Kyoung-Mee, Kim, Seung Tae, Kim, Jinchul, Gavino, Danielle, Benavides, Manuel, Peled, Nir, Nguyen, Timmy, Cusnir, Mike, Eskander, Ramez N, Azzi, Georges, Yoshino, Takayuki, Banks, Kimberly C, Raymond, Victoria M, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli, Kopetz, Scott, Lee, Jeeyun, Odegaard, Justin I

“…To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing. Pan-cancer MSI detection using…”
Get full text

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma by Pal, Sumanta K, Sonpavde, Guru, Agarwal, Neeraj, Vogelzang, Nicholas J, Srinivas, Sandy, Haas, Naomi B, Signoretti, Sabina, McGregor, Bradley A, Jones, Jeremy, Lanman, Richard B, Banks, Kimberly C, Choueiri, Toni K

“…Abstract Background Treatment of metastatic renal cell carcinoma (mRCC) typically entails mechanistically distinct agents across the first- and second-line…”
Get full text

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer by McCoach, Caroline E, Blakely, Collin M, Banks, Kimberly C, Levy, Benjamin, Chue, Ben M, Raymond, Victoria M, Le, Anh T, Lee, Christine E, Diaz, Joseph, Waqar, Saiama N, Purcell, William T, Aisner, Dara L, Davies, Kurtis D, Lanman, Richard B, Shaw, Alice T, Doebele, Robert C

“…Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase ( gene fusions benefit from treatment with ALK…”
Get full text

Genomic profile of advanced breast cancer in circulating tumour DNA by Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.

“…The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical…”
Get full text

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer by Ma, Cynthia X, Bose, Ron, Gao, Feng, Freedman, Rachel A, Telli, Melinda L, Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P, Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J, Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C, Lanman, Richard B, Bryce, Richard, Lalani, Alshad S, Pfeifer, John, Hayes, Daniel F, Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L, Al-Kateb, Hussam, Ellis, Matthew J C

“…Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as…”
Get full text

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing by Schwaederle, Maria, Chattopadhyay, Ranajoy, Kato, Shumei, Fanta, Paul T, Banks, Kimberly C, Choi, In Sil, Piccioni, David E, Ikeda, Sadakatsu, Talasaz, AmirAli, Lanman, Richard B, Bazhenova, Lyudmila, Kurzrock, Razelle

“…Noninvasive genomic profiling of tumors may be possible with next-generation sequencing (NGS) of blood-derived circulating tumor DNA (ctDNA), but proof of…”
Get full text

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma by Ikeda, Sadakatsu, Tsigelny, Igor F., Skjevik, Åge A., Kono, Yuko, Mendler, Michel, Kuo, Alexander, Sicklick, Jason K., Heestand, Gregory, Banks, Kimberly C., Talasaz, AmirAli, Lanman, Richard B., Lippman, Scott, Kurzrock, Razelle

“…Background Because imaging has a high sensitivity to diagnose hepatocellular carcinoma (HCC) and tissue biopsies carry risks such as bleeding, the latter are…”
Get full text

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer by Kapoor, Nimmi S., Curcio, Lisa D., Blakemore, Carlee A., Bremner, Amy K., McFarland, Rachel E., West, John G., Banks, Kimberly C.

“…Background Recently introduced multigene panel testing including BRCA1 and BRCA2 genes for hereditary cancer risk has raised concerns with the ability to…”
Get full text

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay by Schwaederle, Maria, Husain, Hatim, Fanta, Paul T, Piccioni, David E, Kesari, Santosh, Schwab, Richard B, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Parker, Barbara A, Kurzrock, Razelle

“…Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor…”
Get full text

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA by Kaseb, Ahmed O, Sánchez, Nora S, Sen, Shiraj, Kelley, Robin K, Tan, Benjamin, Bocobo, Andrea G, Lim, Kian H, Abdel-Wahab, Reham, Uemura, Marc, Pestana, Roberto Carmagnani, Qiao, Wei, Xiao, Lianchun, Morris, Jeffrey, Amin, Hesham M, Hassan, Manal M, Rashid, Asif, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Mills-Shaw, Kenna R, George, Bhawana, Haque, Abedul, Raghav, Kanwal P S, Wolff, Robert A, Yao, James C, Meric-Bernstam, Funda, Ikeda, Sadakatsu, Kurzrock, Razelle

“…Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular…”
Get full text

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors by Piccioni, David E, Achrol, Achal Singh, Kiedrowski, Lesli A, Banks, Kimberly C, Boucher, Najee, Barkhoudarian, Garni, Kelly, Daniel F, Juarez, Tiffany, Lanman, Richard B, Raymond, Victoria M, Nguyen, Minhdan, Truong, Judy D, Heng, Annie, Gill, Jaya, Saria, Marlon, Pingle, Sandeep C, Kesari, Santosh

“…Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate…”
Get full text

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study by Si, Han, Kuziora, Michael, Quinn, Katie J, Helman, Elena, Ye, Jiabu, Liu, Feng, Scheuring, Urban, Peters, Solange, Rizvi, Naiyer A, Brohawn, Philip Z, Ranade, Koustubh, Higgs, Brandon W, Banks, Kimberly C, Chand, Vikram K, Raja, Rajiv

“…Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non-small cell lung cancer (NSCLC) treated with immune…”
Get full text

Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA by Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.

Get full text

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort by Lee, Jeeyun, Franovic, Aleksandra, Shiotsu, Yukimasa, Kim, Seung Tae, Kim, Kyoung-Mee, Banks, Kimberly C, Raymond, Victoria M, Lanman, Richard B

“…HER2 antagonists have marked activity and are approved for the treatment of HER2 overexpressing breast and gastric cancers. Recent studies have shown that…”
Get full text

Selection criteria for genetic assessment of patients with familial melanoma by Leachman, Sancy A., MD, PhD, Carucci, John, MD, PhD, Kohlmann, Wendy, MS, Banks, Kimberly C., MS, Asgari, Maryam M., MD, Bergman, Wilma, MD, Bianchi-Scarrà, Giovanna, PhD, Brentnall, Teresa, MD, Bressac-de Paillerets, Brigitte, PharmD, Bruno, William, MD, Curiel-Lewandrowski, Clara, MD, de Snoo, Femke A., PhD, Debniak, Tadeusz, MD, Demierre, Marie-France, MD, Elder, David, MBChB, Goldstein, Alisa M., PhD, Grant-Kels, Jane, MD, Halpern, Allan C., MD, Ingvar, Christian, MD, PhD, Kefford, Richard F., MBBS, PhD, Lang, Julie, MD, MacKie, Rona M., MD, Mann, Graham J., MBBS, PhD, Mueller, Kurt, MD, Newton-Bishop, Julia, MD, Olsson, Håkan, MD, Petersen, Gloria M., PhD, Puig, Susana, MD, Rigel, Darrell, MD, Swetter, Susan M., MD, Tucker, Margaret A., MD, Yakobson, Emanuel, PhD, Zitelli, John A., MD, Tsao, Hensin, MD, PhD

“…Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in…”
Get full text

Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients by Porter, Ashleigh, Natsuhara, Mandy, Daniels, Gregory A, Patel, Sandip Pravin, Sacco, Assuntina Gesualda, Bykowski, Julie, Banks, Kimberly C, Cohen, Ezra E W

“…Effective targeted therapy is lacking in head and neck cancer (HNC). The use of next generation sequencing (NGS) has been suggested as a way to potentially…”
Get full text